Medical Genetics · us
CD36 Variant Reveals Gap in Cardiomyopathy Genetic Testing: Estimated to Account for 9% of Disease Burden in People of African Ancestry
A study of more than 80,000 people suggests that a CD36 variant absent from routine testing may explain more of the overall cardiomyopathy burden in people of African ancestry than well-established cardiomyopathy genes. Cleveland Clinic plans to introduce clinical testing for the variant, but whether testing can improve care outcomes remains to be established.
When searching for the genetic causes of cardiomyopathy, a single variant missing from a testing panel could mean overlooking an important clue. A new study led by Cleveland Clinic indicates that a CD36 variant more common in people of African ancestry may contribute substantially to the overall burden of dilated cardiomyopathy, yet is not included in routine cardiomyopathy genetic testing panels.
Published on October 19 in the Journal of the American Medical Association (JAMA), the study analyzed data from 82,623 participants of predominantly African ancestry across four U.S. datasets, comparing the effects of the CD36 Y325* variant, TTN truncating variants, and other established cardiomyopathy genes. The study focused on clarifying the relative contributions of different variants in this population.
People carrying two copies of the CD36 risk variant had approximately 4.8 times the odds of dilated cardiomyopathy compared with noncarriers; those carrying one copy had approximately 1.4 times the odds. These are relative comparisons between groups and cannot be directly converted into an individual's probability of developing the disease, nor do they mean that carrying the variant inevitably leads to illness.
Combining carriers of one and two copies of the variant, the researchers estimated a population attributable fraction of 9% for CD36, higher than the 3.7% for TTN truncating variants. This measure describes the relationship between a variant and the overall disease burden; it does not mean that CD36 alone can establish the cause in nine out of every 100 patients. Even when a common variant has a smaller effect on an individual, its cumulative impact across a population can still be considerable.
Biological evidence already points to a link between CD36 and heart muscle function. A study published in Nature Genetics in 2025 found that loss of CD36 function impaired fatty acid uptake and disrupted metabolism and contraction in cardiomyocytes derived from human induced pluripotent stem cells. This provides a possible mechanism for the genetic association, but cell experiments cannot yet establish that a particular treatment is effective in patients.
Cleveland Clinic said the variant is currently absent from standard cardiomyopathy genetic testing panels and that it plans to introduce testing for it into clinical practice. If testing panels do not adequately reflect the genetic characteristics of populations with different ancestries, gaps in explaining disease causes may remain even after testing. These findings provide a concrete example of that problem.
However, the study was a genetic association analysis using data from U.S. populations, and caution is still needed when extending the findings to other regions. Clinical data are still needed to determine whether adding the test can make diagnoses more complete, change follow-up arrangements, and ultimately improve health outcomes. The most immediate advance is that testing panels are beginning to catch up with the population differences revealed by research.